AI Article Synopsis
- The study focused on β2-microglobulin (β2-MG) as a predictor of prognosis in patients with diffuse large B-cell lymphoma (DLBCL), involving 98 patients over two years.
- The critical threshold for β2-MG was identified as 3.285 µg/L, with patients below this level showing better survival rates compared to those above it during follow-up.
- Elevated levels of β2-MG, along with LDH and CRP, were determined to be independent risk factors influencing overall survival in DLBCL patients, leading to the development of a prognostic prediction model that effectively correlated predicted outcomes with actual results.
Article Abstract
Background: This study investigated the predictive value of β2-microglobulin (β2-MG) on the prognosis of diffuse large B-cell lymphoma (DLBCL) patients.
Methods: Patients with DLBCL diagnosed by pathologic biopsy were collected from January 2021 through December 2022, and a total of 98 patients were finally included. The 98 patients were grouped according to their prognosis, i.e., into the survival group (n = 69) and death group (n = 29). The critical value of β2-MG for survival in DLBCL patients was obtained by ROC curve. Kaplan Meier curve was plotted to analyze the relationship between β2-MG and the overall survival of DLBCL patients, and a one-way test was performed to examine the clinical data of the patients. Independent predictors affecting the prognosis of DLBCL patients were screened using unifactorial and multifactorial Cox regression analysis. R 4.2.1 software was used to refit the constructed column-line graph prediction model and internal validation.
Results: The critical value of β2-MG for survival in DLBCL patients was 3.285 µg/L, obtained by ROC curve. All patients were categorized into the following two groups: β2-MG ≤ 3.285 group (n = 75) and β2-MG > 3.285 group (n = 23). During the follow-up period, 9 endpoint events occurred in the β2-MG ≤ 3.285 group and 20 endpoint events occurred in the β2-MG > 3.285 group. The β2-MG ≤ 3.285 group had a higher overall survival rate than the β2-MG > 3.285 group. High levels of β2-MG, LDH, and CRP were independent prognostic influences affecting overall survival in DLBCL patients. β2-MG, LDH, and CRP were combined to construct the prognostic prediction model, and there was a better consistency between the predicted probability and the actual results.
Conclusions: Poor treatment prognosis of DLBCL patients is closely related to abnormally elevated levels of β2-MG. High levels of β2-MG, LDH, and CRP are independent risk factors for disease progression and prognostic survival in DLBCL patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2024.240907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study focused on β2-microglobulin (β2-MG) as a predictor of prognosis in patients with diffuse large B-cell lymphoma (DLBCL), involving 98 patients over two years.
- The critical threshold for β2-MG was identified as 3.285 µg/L, with patients below this level showing better survival rates compared to those above it during follow-up.
- Elevated levels of β2-MG, along with LDH and CRP, were determined to be independent risk factors influencing overall survival in DLBCL patients, leading to the development of a prognostic prediction model that effectively correlated predicted outcomes with actual results.
Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey.
Regen Ther
March 2025
Novartis Pharma K.K., Tokyo, Japan.
Background: Tisagenlecleucel, an autologous CD19-directed chimeric antigen receptor T-cell therapy, was approved in Japan, in March 2019 for patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukamia and r/r diffuse large B-cell lymphoma, and in August 2022 for patients with r/r follicular lymphoma. Post-approval, a key goal has been to upscale and continuously improve manufacturing and shipment success rates (MSR and SSR, respectively) in the commercial setting to meet the needs of patients worldwide, including in Japan. Herein, we report accrued experience from a 4-year journey of commercial tisagenlecleucel manufacturing process optimization for patients in Japan.
View Article and Find Full Text PDFMYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor - a preliminary analysis.
Ann Hematol
March 2025
Department of Biological Sciences, Minnesota State University Mankato, Mankato, USA.
Article Synopsis
- Diffuse Large B-cell Lymphoma (DLBCL) is a complex disease affecting over 70,000 patients annually, facing treatment challenges despite advancements in therapies like CAR-T.
- Recent findings highlight the importance of genomic alterations, particularly MYC amplification, which is linked to poor responses to CAR-T therapy, and reveal potential new treatment targets associated with this condition.
- Noteworthy genes were identified that are significantly lost in patients with high MYC levels and poor event-free survival, suggesting the need for customized treatment strategies to improve outcomes in these patients.
Prognostic relevance of immunoglobulin heavy chain rearrangement and immunoglobulin kappa light chain rearrangement in patients with diffuse large B cell lymphoma.
Oncologist
March 2025
Department of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.
Purposes: Evidence has demonstrated that monitoring of the variable, diversity, and joining gene segments (VDJ) rearrangement of immunoglobulin (Ig) gene in the circulating tumor DNA (ctDNA) is highly valuable in predicting the prognosis of patients with diffuse large B cell lymphoma (DLBCL). In this study, we investigated the role of both Ig heavy chain (IGH) and Ig kappa light chain (IGK) gene rearrangements detected in ctDNA samples in predicting DLBCL progression.
Methods: Next-generation sequencing (NGS) was used to identify the dominant V(D)J clonotypic rearrangement in tissue samples of 33 DLBCL patients.
Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.
Mater Today Bio
April 2025
Department of Molecular Cell Biology, Amsterdam UMC Location VU, Amsterdam, the Netherlands.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell non-Hodgkin lymphoma, often developing resistance to current treatments. Development and testing of new therapies is hampered by lack of good and models mimicking human disease. Here, we developed a lymphoma-on-chip model to investigate the tumor-supportive roles of lymph node stromal cells (LNSCs) - fibroblastic reticular cells (FRCs) and lymphatic endothelial cells (LECs) - in the DLBCL microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!